BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+18.89%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$26.5B
AUM Growth
+$26.5B
(+6.1%)
Cap. Flow
-$53.2M
Cap. Flow
% of AUM
-0.2%
Top 10 Holdings %
Top 10 Hldgs %
84.24%
Holding
134
New
14
Increased
16
Reduced
60
Closed
7
Top Buys
| 1 |
AbCellera Biologics
ABCL
|
$421M |
| 2 |
Kodiak Sciences
KOD
|
$224M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
$159M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$61.5M |
| 5 |
Aligos Therapeutics
ALGS
|
$44.5M |
Top Sells
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$422M |
| 2 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$410M |
| 3 |
Exact Sciences
EXAS
|
$188M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
$20.2M |
| 5 |
AMRN
Amarin Corp
AMRN
|
$19.7M |
Sector Composition
| 1 | Healthcare | 97.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rhythm Pharmaceuticals
RYTM
$6.75B
| $68.8M | 0.26% |
2,314,873
-156,282
| -6% | -$4.65M |
|
27
Neurocrine Biosciences
NBIX
$13.5B
| $64.9M | 0.24% |
676,975
| – | – |
|
28
Axsome Therapeutics
AXSM
$6.09B
| $63.5M | 0.24% |
778,834
-180,923
| -19% | -$14.7M |
|
|
29
Ultragenyx Pharmaceutical
RARE
$3.04B
| $61.5M | 0.23% |
+444,444
| New | +$61.5M |
|
30
Nurix Therapeutics
NRIX
$723M
| $58.8M | 0.22% |
1,788,921
| – | – |
|
|
BCEL
31
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $57.1M | 0.21% |
3,532,760
| – | – |
|
32
Neurogene
NGNE
$284M
| $53.9M | 0.2% |
3,821,740
| – | – |
|
|
ADAP
33
Adaptimmune Therapeutics
ADAP
$13.9M
| $53M | 0.2% |
9,830,877
+3,500,523
| +55% | +$18.9M |
|
34
Apellis Pharmaceuticals
APLS
$3.51B
| $51.3M | 0.19% |
896,551
| – | – |
|
35
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $49.5M | 0.19% |
2,799,577
| – | – |
|
36
ADC Therapeutics
ADCT
$370M
| $45.4M | 0.17% |
1,418,107
-269,393
| -16% | -$8.62M |
|
|
37
Aligos Therapeutics
ALGS
$75.1M
| $44.5M | 0.17% |
+1,610,000
| New | +$44.5M |
|
|
HZNP
38
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $43.8M | 0.17% |
599,110
-67,390
| -10% | -$4.93M |
|
39
Krystal Biotech
KRYS
$4.35B
| $41.9M | 0.16% |
698,874
-76,318
| -10% | -$4.58M |
|
|
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
| $40.7M | 0.15% |
656,710
-243,111
| -27% | -$15.1M |
|
|
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $39.9M | 0.15% |
920,375
| – | – |
|
|
DBVT
42
DBV Technologies
DBVT
$249M
| $38.3M | 0.14% |
14,614,264
| – | – |
|
|
OPT
43
DELISTED
Opthea Limited American Depositary Shares
OPT
| $37.1M | 0.14% |
+3,308,705
| New | +$37.1M |
|
44
Merus
MRUS
$5.04B
| $35.7M | 0.13% |
2,037,469
| – | – |
|
45
Alkermes
ALKS
$4.95B
| $30.6M | 0.12% |
1,535,149
+176,148
| +13% | +$3.51M |
|
46
Korro Bio
KRRO
$245M
| $30.2M | 0.11% |
856,507
-93,048
| -10% | -$3.28M |
|
47
Protagonist Therapeutics
PTGX
$3.62B
| $29M | 0.11% |
1,436,192
-160,006
| -10% | -$3.23M |
|
48
BioAtla
BCAB
$28.7M
| $28.1M | 0.11% |
+825,000
| New | +$28.1M |
|
|
RETA
49
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $27.7M | 0.1% |
223,976
+170,793
| +321% | +$21.1M |
|
50
Athira Pharma
ATHA
$15.5M
| $27.6M | 0.1% |
806,367
-75,985
| -9% | -$2.6M |
|